Efficacy and Safety of Low-Dose Trimethoprim-Sulfamethoxazole (TMP-SMZ) for the Prevention of Pneumocystis jirovecii pneumonia (PJP) in Non-HIV, Non-Transplant Immunosuppressed Patients: A Real-World Cohort Study
Abstract
Purpose To evaluate the noninferiority and safety of low-dose trimethoprim-sulfamethoxazole (TMP-SMZ, 200/40 mg qd) with respect to conventional-dose TMP-SMZ in preventing Pneumocystis jirovecii pneumonia (PJP) in non-human immunodeficiency virus (HIV), non-transplant, immunosuppressed patients. Methods This retrospective cohort study included patients who received PJP-preventing therapy at the First Affiliated Hospital of Zhejiang University School of Medicine from April 2021 to December 2023. The patients were divided into low-dose group (TMP-SMZ 200/40 mg qd, n=57) and conventional-dose group (400/80 mg qd, n=65). The primary endpoint was the 90-day incidence of PJP, and the secondary endpoints included all-cause mortality and adverse drug events (assessed on the basis of the Common Terminology Criteria for Adverse Events (CTCAE) 5.0 and Kidney Disease: Improving Global Outcomes (KDIGO) criteria). Results No patients in either group developed PJP within 90 days (risk difference (RD) = 0, 95% confidence interval (CI): −0.05 to 0.05). There was no statistically significant difference in the incidence of adverse reactions (ARs), such as hematologic toxicity (granulocytopenia: 5.26% vs 1.54%, p=0.339), liver injury, and kidney injury, between the low-dose group and the conventional-dose group. The median survival time was 193 days in the low-dose group vs 130 days in the conventional-dose group (p=0.312). Conclusion In non-HIV, non-transplant, immunosuppressed patients, the…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 65 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.